

ESDO-FFCD MASTERCLASS II October 5 - 6, 2018 IMMUNOLOGY AND CANCER: FROM BENCH TO BEDSIDE



PALAIS DU PHARO MARSEILLE, FRANCE <http://palaisdupharo.marseille.fr>

International experts will teach on the latest discoveries of Immunotherapy for Digestive Cancers with multidisciplinary views. The 2nd ESDO-FFCD MASTERCLASS is organised during 2 days by the **European Society of Digestive Oncology** and the **Francophone Federation of Digestive Oncology**.

Faculty (preliminary) :

Franck Carbonel, Paris
Nathalie Chaput, Paris
Barbara Fischer, Copenhagen
Ulrich Gueller, St. Gallen
Regis Josien, Nantes
J Larkin, London
Markus Moehler, Mainz
Clara Montagut, Barcelona
Simon Pernot, Paris

Martin Reck, Grosshansdorf
Jens Ricke, Munich
Caroline Robert, Paris
Josep Taberner, Barcelona
Julien Taieb, Paris
David Tougeron, Poitiers
Eric van Cutsem, Leuven
Eric Vivier, Marseille

Organization & Registration:

Liz Tanzer info@esdo.eu tel. +43 676 7076079
ESDO c/o Vienna Medical Academy
1090 Vienna | Alser Strasse 4

Onsite Organization & Accreditation:

Aurélie Gaudron aurelie.gaudron@u-bourgogne.fr
FFCD tel. +33 03 80 38 13 14
21079 DIJON Cedex, 7 Boulevard Jeanne d'Arc

MASTERCLASS II preliminary PROGRAMME

IMMUNOLOGY AND CANCER: FROM BENCH TO BEDSIDE

FRIDAY 5 October 2018

★ **Immunology for Dummies**

General immunology excluding cancer: primary & secondary lymphoid organs, different cellular actors, innate / acquired immunity

Regis Josien
University Hospital Nantes
Julien Taieb, Paris

★ **Immunology and tumours**

immunosurveillance, immunoescape, immunoediting

Nathalie Chaput
Hospital Gustave Roussy Paris

★ **Basis of anti-cancer immunotherapy: mechanisms of action**

Induction of T-cytotoxicity (vaccines, cytokines, adoptive transfer), triggering of innate immune response, checkpoint inhibitors, etc

Eric Vivier
Immunology Centre
Marseille-Luminy

★ **Tumor immunology and diagnosis**

- Future approach to cancer classification
- Immunology-based PET/CT-imaging: where are we now and where are we heading?

Barbara Fischer
Rigshospitalet Copenhagen

★ **Major results of immunotherapy in non-digestive cancers: change of paradigm**

- The example of melanoma
- The example of lung cancers

Martin Reck
Lung Clinic Grosshansdorf

★ **Management of Immunotherapy**

- Practical management of toxicities of immunotherapy in cancer patients
- How to assess the response to immunotherapy? CHOI, RECIST, Immune-Related Response Criteria, depth of response, earliness of response
- Immunomodulation using anti-angiogenic agents
- Microbiote & immunotherapy

Ulrich Gueller
Kantonsspital St. Gallen

Jens Ricke
University Hospital Munich

Simon Pernot
Hospital Georges Pompidou
Paris

Franck Carbonel
Hospital Le Kremlin Bicêtre

MASTERCLASS II preliminary PROGRAMME

IMMUNOLOGY AND CANCER: FROM BENCH TO BEDSIDE

★ The results of immunotherapy in digestive cancers: what happened until 2018?

- non colorectal
- colorectal

David Tougeron

University Hospital Poitiers

Julien Taieb

Hospital Georges Pompidou
Paris

ROUND TABLE DISCUSSION

SATURDAY 6 October 2018

★ How to sequence immunotherapy

J Larkin

London

★ When to discontinue immunotherapy

Caroline Robert

Hospital Gustave Roussy Paris

★ Predictive markers of efficacy

Robert Seagal

or **Clara Montagut**

★ When to discontinue immunotherapy

Caroline Robert

Hospital Gustave Roussy Paris

★ Combination of drugs acting on the immune system

Therapeutic combinations Immuno-chemotherapy /
radiotherapy

Josep Tabernero

Vall d'Hebron Institute of
Oncology Barcelona

★ What therapeutic trials for the future

Therapeutic combinations, resistance mechanisms, new immunomodulatory targets,
cell therapies, novel antibodies, immune conjugates, biomarkers

- non colorectal
- colorectal

Eric van Cutsem

UZ Gasthuisberg Leuven

Markus Moehler

University Hospital Mainz

ROUND TABLE DISCUSSION
